TELO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
745.2K
-57.8%
1.8M
+69.5%
1.0M
-51.2%
2.1M
+86.2%
1.1M
R&D
251.9K
-43.4%
444.7K
-4.9%
467.8K
-63.9%
1.3M
+70.7%
759.5K
SG&A
493.3K
-62.6%
1.3M
+130.2%
573.5K
-31.6%
838.5K
+116.7%
387.0K
Operating Income
-745196
+57.8%
-1764676
-69.5%
-1041336
+51.2%
-2134681
-86.2%
-1146476
EBITDA
-745196
+57.8%
-1764676
-69.5%
-1041336
+51.2%
-2134681
-86.2%
-1146476
Net Income
-705225
+59.0%
-1721528
-73.7%
-990947
+51.9%
-2061193
-87.0%
-1102294
EPS (Basic)
$-0.01
+98.7%
$-0.79
-2533.3%
$-0.03
+50.0%
$-0.06
-100.0%
$-0.03
EPS (Diluted)
$-0.01
+98.7%
$-0.79
-2533.3%
$-0.03
+50.0%
$-0.06
-100.0%
$-0.03
Shares (Diluted)
68.8M
+13.0%
60.8M
+77.0%
34.4M
-0.2%
34.4M
+6.3%
32.4M
Telomir Pharmaceuticals (TELO) — Financials